Aplastic anemia, an unusual hematologic disease, is the paradigm of the human bone
marrow failure syndromes. Almost universally fatal just a few decades ago, aplastic anemia …

Hematopoiesis is the cumulative result of intricately regulated signaling pathways that are
mediated by cytokines and their receptors. Studies conducted over the past 10 to 15 years …

Evidence has accumulated in the recent years further corroborating an immune-mediated
process underlying AA pathogenesis. HSCT from a matched sibling donor is preferred for …

The term congenital neutropenia encompasses a family of neutropenic disorders, both
permanent and intermittent, severe (< 0.5 G/l) or mild (between 0.5-1.5 G/l), which may also …

This review focuses on the classification, diagnosis and natural history of congenital
neutropenia (CN). CN encompasses a number of genetic disorders with chronic neutropenia …

Erythropoietin and Granulocyte-Colony Stimulating Factor Treatment Associated With
Improved Survival in Myelodysplastic Syndrome Page 1 Erythropoietin and Granulocyte-Colony …

Monosomy 7 and interstitial deletion of 7q (− 7/7q−) are well-recognized nonrandom
chromosomal abnormalities frequently found among patients with myelodysplastic …

Eltrombopag (EPAG) received approval from the US Food and Drug Administration for the
treatment of refractory severe aplastic anemia (rSAA) based on treatment of 43 patients with …

Myelodysplastic syndromes (MDS) comprise a group of bone marrow diseases
characterized by profound heterogeneity in morphologic presentation, clinical course, and …

An immune basis for most patients with aplastic anemia (AA) provides a rationale for
immunosuppressive therapy (IST), using antithmyocyte globulin and cyclosporine as one …